Aragon Wins Key Legal Ruling Against Medivation

Aragon Wins Key Legal Ruling Against Medivation 
Aragon Has Exclusive Rights to ARN-509 
SAN DIEGO, CA -- (Marketwire) -- 01/04/13 --  Aragon Pharmaceuticals
Inc., a leader in developing drugs for hormone driven cancers, today
announced that on December 20, 2012, the Superior Court of
California, County of San Francisco, granted summary adjudication in
favor of Aragon on its Complaint in Intervention against Medivation,
holding that Aragon has "exclusive rights to the A-Series compounds,"
including ARN-509. 
On May 3, 2011, Medivation Inc. had filed a breach of contract claim
against the Regents of the University of California claiming rights
to a series of anti-androgen compounds. These compounds were
exclusively licensed to Aragon Pharmaceuticals in 2009. They include
Aragon's lead asset, ARN-509, a novel second-generation anti-androgen
currently in a Phase II clinical trial for advanced
castration-resistant prostate cancer. Judge John E. Munter rejected
Medivation's claims to any interest in ARN-509 and affirmatively held
that Aragon owns the exclusive rights to the A-Series compounds.  
"We are pleased with the recent Court decision upholding our rights
to ARN-509 and remain committed to developing innovative treatments
to help patients suffering from prostate cancer," said Richard A.
Heyman, Ph.D., President and CEO of Aragon Pharmaceuticals. 
About Aragon Pharmaceuticals 
Aragon Pharmaceuticals is focused on the development of 2nd
generation anti-hormonal agents for hormone-driven cancers. The
company's portfolio of small molecule therapeutics is based upon
pioneering research identifying key molecular events that lead to
drug resistance to traditional anti-hormonal therapies. This work has
broad implications for the development of breakthrough medicines for
prostate cancer and other hormone-dependent cancers such as breast,
ovarian and endometrial cancer. Aragon Pharmaceutical's most advanced
compound, ARN-509, is an androgen receptor antagonist that is
currently being evaluated in a Phase 2 trial in patients with
castration-resistant prostate cancer. In addition, Aragon
Pharmaceuticals has a selective estrogen receptor degrader (SERD) for
hormone-sensitive and hormone-resistant estrogen receptor positive
breast cancer targeted to begin clinical trials in 2013. Aragon is a
private company founded in 2009 and headquartered in San Diego,
California. For more information, visit  
www.aragonpharm.com. 
Contact: 
Investor Relations 
Laura Forman
Blueprint Life Science Group
415-375-3340 Ext 103 
 
 
Press spacebar to pause and continue. Press esc to stop.